» Articles » PMID: 24663025

Inhibitors of the Tick-borne, Hemorrhagic Fever-associated Flaviviruses

Overview
Specialty Pharmacology
Date 2014 Mar 26
PMID 24663025
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

No antiviral therapies are available for the tick-borne flaviviruses associated with hemorrhagic fevers: Kyasanur Forest disease virus (KFDV), both classical and the Alkhurma hemorrhagic fever virus (AHFV) subtype, and Omsk hemorrhagic fever virus (OHFV). We tested compounds reported to have antiviral activity against members of the Flaviviridae family for their ability to inhibit AHFV replication. 6-Azauridine (6-azaU), 2'-C-methylcytidine (2'-CMC), and interferon alpha 2a (IFN-α2a) inhibited the replication of AHFV and also KFDV, OHFV, and Powassan virus. The combination of IFN-α2a and 2'-CMC exerted an additive antiviral effect on AHFV, and the combination of IFN-α2a and 6-azaU was moderately synergistic. The combination of 2'-CMC and 6-azaU was complex, being strongly synergistic but with a moderate level of antagonism. The antiviral activity of 6-azaU was reduced by the addition of cytidine but not guanosine, suggesting that it acted by inhibiting pyrimidine biosynthesis. To investigate the mechanism of action of 2'-CMC, AHFV variants with reduced susceptibility to 2'-CMC were selected. We used a replicon system to assess the substitutions present in the selected AHFV population. A double NS5 mutant, S603T/C666S, and a triple mutant, S603T/C666S/M644V, were more resistant to 2'-CMC than the wild-type replicon. The S603T/C666S mutant had a reduced level of replication which was increased when M644V was also present, although the replication of this triple mutant was still below that of the wild type. The S603 and C666 residues were predicted to lie in the active site of the AHFV NS5 polymerase, implicating the catalytic center of the enzyme as the binding site for 2'-CMC.

Citing Articles

-Heterocycles as Promising Antiviral Agents: A Comprehensive Overview.

Ahmad G, Sohail M, Bilal M, Rasool N, Qamar M, Ciurea C Molecules. 2024; 29(10).

PMID: 38792094 PMC: 11123935. DOI: 10.3390/molecules29102232.


Powassan Virus Encephalitis.

Piantadosi A, Solomon I Infect Dis Clin North Am. 2022; 36(3):671-688.

PMID: 36116842 PMC: 9494578. DOI: 10.1016/j.idc.2022.03.003.


T-Cell Immunoglobulin and Mucin Domain 1 (TIM-1) Is a Functional Entry Factor for Tick-Borne Encephalitis Virus.

Zhang X, Liang C, Wang H, Guo Z, Rong H, Pan J mBio. 2022; 13(1):e0286021.

PMID: 35073759 PMC: 8787471. DOI: 10.1128/mbio.02860-21.


The Compound SBI-0090799 Inhibits Zika Virus Infection by Blocking Formation of the Membranous Replication Compartment.

Riva L, Goellner S, Biering S, Huang C, Rubanov A, Haselmann U J Virol. 2021; 95(22):e0099621.

PMID: 34468177 PMC: 8549497. DOI: 10.1128/JVI.00996-21.


6-Azauridine Induces Autophagy-Mediated Cell Death via a p53- and AMPK-Dependent Pathway.

Cha Y, Park R, Jang M, Park Y, Yamamoto A, Oh W Int J Mol Sci. 2021; 22(6).

PMID: 33799444 PMC: 8000275. DOI: 10.3390/ijms22062947.


References
1.
Sofia M, Chang W, Furman P, Mosley R, Ross B . Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase. J Med Chem. 2011; 55(6):2481-531. DOI: 10.1021/jm201384j. View

2.
Kelley L, Sternberg M . Protein structure prediction on the Web: a case study using the Phyre server. Nat Protoc. 2009; 4(3):363-71. DOI: 10.1038/nprot.2009.2. View

3.
Neyts J, Meerbach A, McKenna P, De Clercq E . Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections. Antiviral Res. 1996; 30(2-3):125-32. DOI: 10.1016/0166-3542(96)89697-5. View

4.
Dodd K, Bird B, Khristova M, Albarino C, Carroll S, Comer J . Ancient ancestry of KFDV and AHFV revealed by complete genome analyses of viruses isolated from ticks and mammalian hosts. PLoS Negl Trop Dis. 2011; 5(10):e1352. PMC: 3186760. DOI: 10.1371/journal.pntd.0001352. View

5.
Holbrook M . Kyasanur forest disease. Antiviral Res. 2012; 96(3):353-62. PMC: 3513490. DOI: 10.1016/j.antiviral.2012.10.005. View